Press Releases

Year 2008

Wockhardt’s Q2 Results 2008   Sales grow by 48.3% to Rs. 935 crore Operating Profit up by 51.6%   July 28, 2008 Wockhardt’s Q1 Results 2008   Sales up by 50% to Rs. 786 crores Operating Profit up by 50%   April 28, 2008 “A HUMANE BUDGET”   Habil Khorakiwala Wockhardt Chairman & FICCI past-President reacts to the Union Budget   February 29, 2008 Wockhardt’s Robust Annual Results   Sales surge by 53% to Rs. 2,653 crore Net Profit soars by 60% to Rs. 386 crore Operating Margin at 24.1% up 90 basis points   February 20, 2008 Wockhardt enters the US market with generic version of Zithromax   Gets US FDA nod to launch generic version of the broad-spectrum antibiotic   February 13, 2008 Wockhardt to restructure its R&D business     January 30, 2008 Wockhardt to launch generic version of anti-depressant Zoloft in the US market   Gets US FDA approval for Sertraline tablets   January 09, 2008 Wockhardt enters billion-dollar anti-allergic Zyrtec market in the US   Gets US FDA nod for Cetirizine, anti-allergic OTC   January 01, 2008

Year 2007

Wockhardt acquires Morton Grove in the US   Boost To US Revenue Through Expanded Product Portfolio   October 24, 2007 Wockhardt’s Q3 Results 2007   Wockhardt’s Net Profits up by 46% Operating Margins 24.5% up by 2.3%   October 23, 2007 Wockhardt to market SAMMY – a process patented tablet for Osteoarthritis   Wockhardt signs in-licensing agreement with Italian firm to strengthen Pain relief portfolio Mumbai, October 17, 2007   October 17, 2007 Wockhardt to market innovative Zindaclin cream, A Patented ‘Once-a-day’ treatment for Acne cure   Wockhardt to market innovative Zindaclin cream A Patented ‘Once-a-day’ treatment for Acne cure   October 31, 2007 Wockhardt gets US FDA nod to enter the US$ 2.6 billion Norvasc market   Wockhardt gets US FDA nod to enter the US$ 2.6 billion Norvasc market Launch of anti-hypertensive Amlodipine tablets   September 18, 2007 Wockhardt’s Q2 Net Profit, Crosses the Rs. 100 Crore Mark, Consolidated Sales rise by 53% at Rs. 630 Crores, Net Profits increase by 62% at Rs. 102 Crores   Wockhardt’s Q2 Net Profit Crosses the Rs. 100 Crore Mark Consolidated Sales rise by 53% at Rs. 630 Crores Net Profits increase by 62% at Rs. 102 Crores   July 25, 2007 Wockhardt to launch anti-epileptic injection, Fosphenytoin, in the US, Day 1 launch upon patent expiration   Wockhardt to launch anti-epileptic injection, Fosphenytoin, in the US Day 1 launch upon patent expiration   July 09, 2007 Wockhardt to launch Cefprozil, in the US, Eight FDA approval in 4 months   Wockhardt to launch Cefprozil, in the US Eight FDA approval in 4 months   June 20, 2007 Wockhardt gets US FDA nod to enter the $680 million Lamisil market, Seventh ANDA approval in 3 months   Wockhardt gets US FDA nod to enter the $680 million Lamisil market Seventh ANDA approval in 3 months   June 06, 2007 Wockhardt launches insomnia drug Zolpidem in the US, Six US FDA approvals in two months   Wockhardt launches insomnia drug Zolpidem in the US Six US FDA approvals in two months   May 21, 2007 Wockhardt completes the acquisition of Negma Laboratories in France, Becomes the largest Indian pharmaceutical company in Europe   Wockhardt completes the acquisition of Negma Laboratories in France   May 18, 2007 Wockhardt acquires Negma Laboratories in France, Becomes the largest Indian pharmaceutical company in Europe   Wockhardt acquires Negma Laboratories in France Becomes the largest Indian pharmaceutical company in Europe   May 03, 2007 Wockhardt Sales soars by 49% in Q1, Operating Profit surges by 68%   Wockhardt Sales soars by 49% in Q1 Operating Profit surges by 68%   April 26, 2007 Wockhardt receives US FDA approval for anti-hypertensive drug   Wockhardt receives US FDA approval for anti-hypertensive drug Five FDA approvals in five weeks   April 26, 2007 Wockhardt to launch Italy’s B-Lift range, of dermatology products in India   Wockhardt to launch Italy’s B-Lift range of dermatology products in India   April 23, 2007 Wockhardt to soon introduce Kelocote to treat scars   Wockhardt to soon introduce Kelocote to treat scars   April 17, 2007 Wockhardt gets US FDA nod to market full range of Ceftriaxone antibiotic injection in US   Wockhardt gets US FDA nod to market full range of Ceftriaxone antibiotic injection in US   April 16, 2007 Wockhardt receives US FDA approval for anti-inflammatory injection   Wockhardt receives US FDA approval for anti-inflammatory injection   March 28, 2007 Wockhardt receives US FDA approval for diuretic injection, Second FDA approval in a week   Wockhardt receives US FDA approval for diuretic injection Second FDA approval in a week   March 28, 2007 Wockhardt to market painkiller in the US, Sixteenth US FDA-approved product   Wockhardt to market painkiller in the US Sixteenth US FDA-approved product   March 20, 2007 Wockhardt Fourth Quarter Net Profit Up 20% at Rs. 87crores, Sales Up 44% at Rs. 526 crores   Wockhardt Fourth Quarter Net Profit Up 20% at Rs. 87crores Sales Up 44% at Rs. 526 crores   February 22, 2007 Wockhardt signs in-licensing pact with Crawford Healthcare of UK, Launches Vitix for vitiligo skin disorder   Wockhardt signs in-licensing pact with Crawford Healthcare of UK Launches Vitix for vitiligo skin disorder   January 22, 2007

Press Releases Archives Year 2006 Year 2005

Would like to know more about Wockhardt ? Annual Report 2007 Corporate Presentation Chairman’s Letter to Shareowners Investor Update Quarterly Results

For press enquiries about Wockhardt, please contact Daryl Suchitha Associate Vice President - Corporate Relations Wockhardt Limited Wockhardt Towers, Bandra-Kurla Complex, Bandra East, Mumbai 400 051, India. Tel. : + 91 - 22 - 2653 4444.    Extension: 6303 Direct Tel.: + 91 - 22 - 2659 6303 Fax: + 91 - 22 - 2653 4242 Email: daryls@wockhardt.com

Disclaimer:
The company would like to caution that any forward-looking statements or projections made by the company, including those made in the press release announcements, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.